01:30 , Jan 8, 2014 |  BC Extra  |  Financial News

Isarna raises EUR 13 million in venture round

Isarna Therapeutics GmbH (Regensburg, Germany) raised EUR 13 million ($17.7 million) in an undisclosed venture round from new investor AT NewTec and existing investor MIG. Isarna (formerly Antisense Pharma GmbH ) is developing trabedersen (...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Apceth management update

Apceth GmbH & Co. KG , Munich, Germany   Business: Gene/Cell therapy   Hired: Stefanos Theoharis as CBO, a newly created position, formerly head of business development at Antisense Pharma GmbH  ...
08:00 , Mar 4, 2013 |  BC Week In Review  |  Clinical News

Trabedersen: Phase II start

Next half, Antisense will begin a 2-stage Phase II trial to evaluate systemic IV trabedersen in patients with malignant melanoma, pancreatic cancer and other tumors. The first stage includes a dose-confirmatory component, while the second...
07:00 , Jul 30, 2012 |  BC Week In Review  |  Clinical News

Trabedersen regulatory update

FDA granted Orphan Drug designation for Antisense's trabedersen to treat malignant melanoma. The transforming growth factor (TGF) beta 2 antisense oligonucleotide is in Phase I/II testing in patients with pancreatic adenocarcinoma, malignant melanoma or colorectal...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Clinical News

Trabedersen: Phase III discontinued

In January, Antisense terminated the open-label, international Phase III SAPPHIRE trial of trabedersen for second-line treatment of anaplastic astrocytoma or secondary glioblastoma (GBM) due to slow patient recruitment. The company said the delays were due...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Clinical News

Trabedersen: Additional Phase I/II data

Additional data from the open-label, dose-escalation Phase I/II P001 trial in 61 previously treated patients showed that IV trabedersen for 4 or 7 consecutive days of a 2-week cycle for up to 10 cycles was...
07:00 , Jul 11, 2011 |  BC Week In Review  |  Company News

Antisense Pharma management update

Antisense Pharma GmbH , Regensburg, Germany   Business: Cancer   Transitioned: Hubert Heinrichs to acting CEO while remaining managing director and CMO; he replaces Karl-Hermann Schlingensiepen  ...
07:00 , Jul 11, 2011 |  BC Week In Review  |  Financial News

Antisense Pharma completes venture financing

Antisense Pharma GmbH , Regensburg, Germany   Business: Cancer   Date completed: 7/6/11   Type: Venture financing   Raised: €8 million ($11.6 million)   Investor: MIG Funds  ...
00:18 , Jul 7, 2011 |  BC Extra  |  Financial News

Antisense raises EUR 8M as CEO steps aside

Antisense Pharma GmbH (Regensburg, Germany) raised EUR 8 million ($11.6 million) from existing investors MIG Funds and Global Asset Fund. Antisense Pharma said founder Karl-Hermann Schlingensiepen stepped aside as CEO last week; he will now...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Clinical News

Trabedersen: Phase IIb data

An open-label, international Phase IIb trial in 134 evaluable patients with recurrent or refractory anaplastic astrocytoma or GBM showed that 10 µM trabedersen non-significantly improved tumor control rate at 6 and 14 months vs. standard...